Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
9 METERS BIOPHARMA, INC. (NMTR)
Sector: Healthcare; Industry: Biotechnology

9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company is based in Raleigh, North Carolina.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-04-05 Temperato John Chief Executive Officer Buy 100,000 $1.00 $100,000 No
2021-04-05 Sitar Edward J Chief Financial Officer Buy 50,000 $1.00 $50,000 No
2020-12-15 Temperato John Chief Executive Officer Buy 153,846 $0.65 $100,000 No
2020-12-15 Sirgo Mark A Director Buy 230,769 $0.65 $150,000 No
2020-12-15 Sitar Edward J Chief Financial Officer Buy 61,538 $0.65 $40,000 No
2020-09-11 Sirgo Mark A Director Buy 148,485 $0.65 $96,364 No
2020-08-21 Temperato John Chief Executive Officer Buy 70,000 $0.69 $48,300 No
2020-08-20 Constantino Michael T. Director Buy 34,108 $0.75 $25,581 No
2020-08-17 Sirgo Mark A Director Buy 100,000 $0.56 $56,000 No
2020-08-17 Temperato John Chief Executive Officer Buy 35,000 $0.57 $19,831 No
2020-06-15 Sirgo Mark A Director Buy 17,943 $0.60 $10,721 No
2020-06-15 Temperato John Chief Executive Officer Buy 10,000 $0.60 $5,971 No
2019-06-28 Laumas Sandeep CEO, Executive Chairman Buy 4,000 $1.15 $4,600 No
2019-06-13 Laumas Sandeep CEO, Executive Chairman Buy 1,000 $1.22 $1,216 No
2019-05-30 Madan Jay P. President Buy 5,000 $1.32 $6,600 No
2019-05-24 Proujansky Roy Director Buy 1,000 $1.28 $1,280 No
2019-05-22 Laumas Sandeep CEO, Executive Chairman Buy 5,000 $1.38 $6,900 No
2018-11-30 Proujansky Roy Director Buy 1,400 $2.63 $3,682 No
2018-11-30 Laumas Sandeep Executive Chairman Buy 3,000 $2.63 $7,890 No
2018-11-29 Prior Christopher P. Chief Executive Officer Buy 5,000 $2.75 $13,750 No
2018-11-29 Laumas Sandeep Executive Chairman Buy 3,000 $2.56 $7,670 No
2018-09-14 Prior Christopher P. Chief Executive Officer Buy 200 $5.82 $1,164 No
2018-09-12 Prior Christopher P. Chief Executive Officer Buy 500 $6.13 $3,065 No
2018-09-07 Laumas Sandeep Executive Chairman Buy 500 $6.10 $3,050 No
2018-08-30 Laumas Sandeep Executive Chairman Buy 500 $5.24 $2,620 No
2018-08-30 Prior Christopher P. Chief Executive Officer Buy 309 $5.20 $1,607 No
2018-08-28 Laumas Sandeep Executive Chairman Buy 250 $4.90 $1,225 No
2018-08-28 Prior Christopher P. Chief Executive Officer Buy 1,000 $4.93 $4,930 No
2018-08-28 Laumas Sandeep Executive Chairman Buy 750 $5.01 $3,759 No
2018-08-27 Almenoff June Sherie COO and Chief Medical Officer Buy 1,400 $4.92 $6,885 No

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.